CGT Industry Upgrade Series - Shenzhen Weiguang Life Science Park & Bay Gravity Event Showcases Leading Experts and Innovation Ecosystem
Event Information
■ Stop 8: Shenzhen Weiguang Life Science Park & Bay Gravity
Event Time: 13:00, Thursday, April 25, 2024
Event Venue8th Floor, Building 1B, Weiguang Life Science Park, Guangming District, Shenzhen: Bay Gravity (Guangming Biomedical Innovation Center)
OrganizerHealthcare Innovative Ecosystem Alliance (HIEA)
Co-Hosted By: Hangcheng Biotech, Yeasen Biotechnology, Lepu Biopharma, Vigene Biosciences, Danaher Life Sciences, DeepResearch Bio, Lingfu Top Biotech, Hanhuang Technology, Legend Capital
Organizer: VCBeat New Medicine
Co-organizers: Weiguang Life Science Park, Shidai Gaoke, Bay Gravity (Guangming Biomedical Innovation Center)
Shenzhen Weiguang Life Science Park: Actual View
Wan You Yin Li: Real Scene:
Event Scale: 50 people/session
Event Collaboration:
Ms. Fu 17851017836 (WeChat ID same)
Event Registration:
Capillaries 17782369627 (WeChat ID same)
Highlights
CGT from an Investment Perspective: Leveraging investor acumen to distill new pathways for capital operations of innovative pharmaceutical companies during discussions on investment and financing strategies in the CGT sector, thereby helping enterprises seize growth opportunities and navigate challenges.
Optimal Supply Chain Solution: Listen to Party A's needs, and supply chain enterprises will work together to explore the most suitable solutions, striving to help innovative companies transition smoothly, rapidly, and cost-effectively from IND to BLA.
Global Insights · CGT Quality Management: Focusing on the frontier, we delve into comprehensive quality control throughout the cell and gene therapy lifecycle. We uncover the impact of global regulations, analyze successful case studies, and empower enterprises to build efficient, compliant systems, safeguarding the safe delivery of innovative therapies to patients.
[Industry Leaders Are Here]: Top industry leaders will be present in person to interpret the quality lifeline of CGT products within a global framework, reveal the essence of quality control at every stage, and jointly map out a blueprint for CGT product quality targeting the global market.
[Commercialization of Laboratory Achievements]: Scientists, entrepreneurs, investors, and supply chain experts join forces to discuss the collaborative secrets behind bridging the “Valley of Death” from laboratory breakthroughs to industrialization.
[Addressing Hot Topics]: In the face of an economic downturn and intensifying global competition, how can CGT companies defy the odds and thrive amid a capital winter, rivaling the “300 Million Yuan Club”? And how should they collaborate with supply chain partners to “safely” expand overseas and pioneer new blue-ocean opportunities in international markets?
Shenzhen Weiguang Life Science Park——As a key engine for the CGT industry in South China, and as China’s first specialized biomedical park featuring the commercialization of synthetic biology achievements, its prominent innovative vitality and pragmatic spirit of industrial cooperation have provided a solid foundation for innovation in the CGT sector.
Bay Gravity——Co-established by the Guangming District Government and Shenzhen Bay Laboratory, it focuses on source innovation projects, fully supports scientists and physicians in their entrepreneurial and innovative endeavors, provides a one-stop acceleration experience, and empowers biopharmaceutical startups to grow from the ground up and realize their innovative value.
The “Shenzhen Weiguang Life Science Park & Bay Area Gravity” event marks the eighth stop in the Park Tour series. Similar events will be held in other parks in the future to promote the continuous upgrading and development of the CGT industry. We look forward to engaging in discussions and fostering mutual progress with industry peers, thereby helping the CGT industry go further!
Event Agenda
■ 13：00-13：30
Visit to Weiguang Life Science Park, Shenzhen Academy of Medical Sciences, and Bay Gravity (Guangming Biomedical Innovation Center)
■ 13：30-13：35
Host's Opening Remarks
Xiao Liu | Vice President of Business and Marketing at Xingcheng Biotech, Deputy Director of the MAH Special Committee of the Chinese Pharmaceutical Enterprise Management Association
■ 13：35-13：40
Address by the Park Leadership
Li Jiasheng | Executive Deputy General Manager, Weiguang Life Science Park Development Company
Wu Tong | Director of Operations, Bay Gravity
■ 13：40-14：00
Keynote Speech 1【Industry Leaders Are Here】| Quality Management Across the Full Lifecycle of CGT Products from a Global Perspective
Du Xin | CEO of Egrin Pharmaceuticals, Former FDA Reviewer
■ 14：00-14：20
Keynote Speech 2 |Cutting-Edge Technologies Accelerate the R&D of Cell and Gene Therapies
Zhou Jinghui | Senior Technical Marketing Scientist, Danaher Life Sciences
■ 14：20-14：40
Keynote Speech 3 | Preparation and Evaluation of Animal Disease Models
Yunting Wei | Project Director & Marketing Director, Lingfu Top Biotech
■ 14：40-15：00
Keynote Speech 4 | Overview of the CAR-T Cell Therapy Industry
Xingxing Bu | Hanhuang Technology Senior Product Manager
■ 15：00-15：50
Panel 1 | How to Partner with CGT Companies to Navigate from IND to BLA: Steadily, Swiftly, and Cost-Effectively?
· Introduction to Core Competencies and Service Value
· How to Engage Constructively with Clients on a Professional Level and Foster Mutual Support
Huang Weidong | Senior Director of Process R&D, Yuanxing Gene
Li Junhui | Vice President of Science, Technology and Production, Xingcheng Biotech
Zhou Jinghui | Danaher Life Sciences, Senior Technical Marketing Scientist
Yi Yanqiong | CEO, Lingfu TopBio
Bu Xingxing | Senior Product Manager, Hanhuang Technology
Geng Shaojun | Co-founder, Tongli Haiyuan Biology
Wei Na | Assistant President, CytoMedic
Yu Xiaoyu | R&D Director, CGT, LePure Biotech
■ 15:50–16:10 Tea Break
■ 16：10-17：00
Panel 2 [Site Features]| Discussing the Translation of Scientific Research Achievements: From Laboratory to Industrialization, How Should All Parties Cooperate and Collaborate?
· Difficulties and Challenges in the Translation of Frontier Achievements
· Breaking Through the Bottleneck of Technology Maturation
· Stakeholders’ Focus Areas and Collaboration in Technology Transfer
Xu Zeli | Director of Translational Services, Shenzhen Medical Academy
Yuxuan Cai | Distinguished Researcher, Shenzhen Bay Laboratory
Chen Zhicheng | Senior Researcher, Center for Translational Medicine, Shenzhen Bay Laboratory
Kang Xi | Researcher, Gene and Cell Therapy Platform, Center for Translational Medicine, Shenzhen Bay Laboratory
Wang Wenhao | Director of Biomaterials R&D, Zhongke Ruiji
Tong Du | R&D Director, Laiman Bio
Zhou Qihao | Vice President, Yeasen Biotechnology
Huang Rui | Executive President, GenScript Biotech
Liu Bin | Chief Marketing Officer, Shenyan Bio
■ 17：00-17：20
Keynote Speech 5 |Progress and Trends in the CGT Industry from an Investment Perspective
· Finance as a Tool: Understanding Capital Market Trends
· Industry as the Foundation: Current Status and Outlook of the CGT Sector
Dong Ao | Investment Manager, Legend Capital
■ 17：20-18：00
Panel 3 [Hot Topics Inside]| How Can CGT Companies Effectively “Raise and Spend Capital” in the New Landscape?
· Hot Topic 1: The $30 Million Man in the Winter
· Hot Topic 2: How R&D and Supply Chain Companies Can Expand Overseas “Safely”
Li Yuanyuan | CEO, Sanqi Biotech
Zhou Yuan | Senior Vice President, Alpha Regenerative Medicine
Li Fusheng | Chairman, Navi Vaccine
Yang Zhenhuang | Founder & CEO of IDBIO
Wang Mingjun | InnoImmune, Executive Vice President and CEO
Chen Yi | CFO, RegeneBio
Chen Xin | Senior Investment Director, Yuansheng Venture Capital
Ji Qianqian | Shenzhen High-Tech Venture Capital, Senior Investment Manager
Dong Ao | Legend CapitalInvestment Manager
Wu Chao | General Manager, Artery New Medicine (Moderator)
■ 18:30-20:30 Dinner Reception (By Invitation Only)
Guest Introduction
Liu Xiao
Xingcheng Bio, Vice President of Business and Marketing,
Vice Chair of the MAH Special Committee, China Pharmaceutical Enterprise Management Association
Xiao Liu, Ph.D. in Strategy from the University of Montpellier (France); EMBA from Nankai University; M.Sc. in Biology from the University of Manchester; postgraduate studies in Finance at the University of Hong Kong; currently pursuing an M.Sc. in Psychology at Arizona State University (USA). UCMT Industry Professor; Honorary Director of GDA. Senior Engineer in Measurement, Testing, and Instrumentation across China. Thesis Advisor for Doctoral programs in Health Management and Business Administration (DBA/Ph.D.) and the MBA program at the University of Montpellier (France); Distinguished Lecturer for workshops at the Business School of the University of Hong Kong and Nankai University Business School; Instructor for the Advanced Leadership Training Program in Biopharmaceuticals at Peking University Health Science Center; Guest Lecturer at Yihong Business School. Vice Chairman of the MAH Special Committee under the Chinese Pharmaceutical Enterprise Management Association; Chief Researcher at the Life Sciences Enterprise Research Center of E-Drug Manager; Special Researcher at the China Biomedical Infrastructure Alliance. Planner and Host of the “ChatCGT” column.
Previously served as Head of Marketing for Greater China at Danaher Biotechnology Group, and held positions including Asia-Pacific Marketing Director, Greater China Marketing Director, Consumables Sales Manager, Business Development Manager, and Product Manager at companies such as Cytiva, GE Life Sciences, PerkinElmer, and Thermo Fisher Scientific.
Li Jiasheng
Weiguang Life Science Park Development Co., Ltd. Executive Deputy General Manager
Li Jiasheng, during his tenure as Director of Infrastructure at Weiguang Biologics, spearheaded the planning and construction of the Weiguang Life Science Park, establishing a benchmark for the “vertical industrialization” of biopharmaceuticals in Shenzhen and even the Greater Bay Area. His efforts earned multiple authoritative recognitions and significantly promoted the clustering of emerging industries in Guangming District. Later serving as Executive Deputy General Manager, he successfully facilitated the establishment of the Shenzhen Academy of Medical Sciences within the park, closely aligning with various stakeholders’ needs to support the implementation of the Academy’s strategic layout. Furthermore, representing Shenzhen Weiguang Life Technology Holding Group, he co-founded the Bay Area Gravitational Biopharmaceutical Innovation Center in collaboration with Shenzhen Bay Laboratory. Through efficient operations focused on incubating enterprises with disruptive innovative technologies, he played a pivotal role in advancing the high-end and sustainable development of the biopharmaceutical industry in Guangming District.
Wu Tong
Bay Gravity, Operations Director
Dr. Wu Tong studied under Academician Gao Shaorong at the National Institute of Biological Sciences, Beijing. She previously served as a postdoctoral fellow and lecturer at the Harvard Stem Cell Institute and the Center for Regenerative Medicine of Massachusetts General Hospital. Dr. Wu has published multiple research articles as the first or co-first author in top-tier journals such as Science and Biomaterials, secured several U.S. research grants, and was invited to deliver presentations at the North American Thoracic Surgery Annual Meeting on multiple occasions. Upon returning to China, she served as a Senior R&D Scientist at a leading gene-editing company and concurrently acted as a Scientific Advisor for a private equity investment firm focused on life sciences. She is currently the Director of Operations at Shenzhen Bay Gravity Technology Co., Ltd. Dr. Wu possesses extensive expertise and experience in basic life sciences research, drug development, translation of scientific achievements, and venture capital financing.
Du Xin
CEO of Eglin Pharmaceuticals, Former FDA Reviewer
Dr. Xin Du earned his Ph.D. from the University of Florida and completed his postdoctoral training at the National Institutes of Health (NIH). He has previously worked at the U.S. Food and Drug Administration (FDA) and pharmaceutical companies including Aventis-Pasteur, Wyeth, Novartis, Bristol Myers Squibb (BMS), NPS Pharmaceuticals, Actinium Pharmaceuticals, Advaxis, and Adlai Nortye. Currently, he serves as CEO of Eglin Pharma, a member of the Board of Directors of SAPA, and Secretary-General of the FDA Experts Association. Dr. Du possesses extensive experience in biopharmaceuticals and small-molecule products, with unique expertise in drug registration and regulatory affairs that bridges both the FDA and industry perspectives. He has an in-depth understanding of FDA and global regulations governing drug development, manufacturing, quality management, clinical design, and clinical trials, earning him the reputation as a “cross-boundary regulatory expert between the FDA and industry.” Within a single year, he helped secure approval for two biologic licenses, accounting for half of all biologic license approvals granted by the FDA’s Center for Biologics Evaluation and Research (CBER) that year. He also obtained critical manufacturing license approvals, thereby preserving over $100 million worth of product inventory and exclusive marketing rights.
Zhou Jinghui
Danaher Life Sciences Senior Technical Marketing Scientist
Zhou Jinghui, a graduate of South China University of Technology, currently serves as a Senior Technical Marketing Scientist for the Danaher Life Sciences Platform. He is primarily responsible for developing and promoting comprehensive solutions for the life sciences platform, organizing offline marketing events, driving business development, and managing the laboratory at the MDS Life Sciences Research Institute. Previously, he held technical support roles at companies such as Qiagen Biotechnology, Eppendorf AG, and 3D Medicines Inc. Mr. Zhou has extensive experience in the fields of translational medicine and genetic testing, with particular expertise in next-generation sequencing (NGS) and quantitative PCR (qPCR).
Wei Yunting
Lingfu Tuopu Biology, Project Director, Marketing Director
Wei Yunting,Hunan Agricultural University Master's degree holder, participated in the National 973 Program research during graduate studies, studied under Academician Guan Chunyun, with years of experience in project design and management, possessing rich insights into overall scientific research design and control.
Bu Xingxing
Hanhuang Technology Senior Product Manager
Bu Xingxing serves as a Product Manager at Jiangsu Hanhuang Technology Co., Ltd., a wholly-owned subsidiary of Jiangsu Hanbang Technology Co., Ltd. He graduated from Sichuan Agricultural University in 2014 with a major in Biochemistry and Molecular Biology. In 2016, he joined Hanbang Technology, where he participated in the R&D design and marketing promotion of laboratory-scale biomacromolecule chromatography systems and ultrafiltration systems. He is well-versed in various application scenarios for purification equipment targeting both large and small molecules. He possesses expertise in selecting separation and purification equipment as well as ultrafiltration devices for fields including monoclonal antibodies, bispecific antibodies, recombinant proteins, mRNA, plasmids, vaccines, cell therapy, gene therapy, and IVD raw materials. He is capable of assisting users in implementing projects from R&D through to pilot-scale production.
Huang Weidong
Yuanxing Gene, Senior Director of Process R&D
Huang Weidong, Senior Director of Process R&D, Senior Engineer in Biopharmaceuticals, and National Licensed Pharmacist. He is responsible for the development of manufacturing processes and product production management for viral vector-based gene therapies, including adenovirus, lentivirus, and poxvirus vectors, at Yuanxing Gene. He has led process development for nearly 100 viral vector projects and possesses 20 years of experience in CMC research for viral vectors, along with extensive GMP management expertise.
Li Junhui
Xingcheng Biotech: Vice President of Science, Technology and Production; CTO
Li Junhui, Ph.D. in Biochemical Engineering, graduated from East China University of Science and Technology. Holds an MBA from Antai College of Economics and Management, Shanghai Jiao Tong University. Possesses nearly 20 years of experience in the R&D and industrialization of biopharmaceuticals. Previously served as Production Director at Shanghai ICT Co., Ltd.; and as Manager and Director at Shanghai RAAS Blood Products Co., Ltd., overseeing R&D, regulatory affairs, and quality management. Proficient in plasmid and lentiviral vector manufacturing processes, CAR-T cell preparation, and quality control. Well-versed in process development for mammalian cell culture platforms. Experienced in upstream process development and GMP manufacturing of viral vectors. Successfully secured IND approvals for multiple projects. Demonstrates extensive team management expertise.
Geng Shaojun
Co-Founder, Tongli Haiyuan Biotech
Geng Shaojun holds an MBA from the University of Management and Technology (UMT) in the United States. He is a member of the Biopharmaceutical Innovation Association and the Medical-Engineering Interdisciplinary Association, with over 20 years of team management experience. For the past decade, he has been engaged in the cell therapy and gene therapy industries, possessing in-depth knowledge of the upstream sector. Committed to the steady growth of startups, he focuses on corporate strategic planning and culture building, industry landscape research, and business model design. He has facilitated collaborative partnerships with multiple universities and participated in the filing of two invention patents. He brings extensive practical experience in building teams from scratch, designing and optimizing organizational structures, initiating key product projects, and comprehensive operational management.
Weina
Assistant President, SaiFu Pharma
Weina,General Manager/Institutional Head of Shenzhen Center (Saifu Jiayuan); Secretary-General of the Mutagenesis Professional Committee, Chinese Society of Environmental Mutagens. Completed preclinical safety evaluation studies for approximately 55 cell and gene therapy (CGT) drugs, and obtained IND and NDA approvals from the Center for Drug Evaluation (CDE) for 14 CGT drugs.
Xu Zeli
Shenzhen Medical Academy of Research and Translation, Director of Translational Services
Xu Zeli,Previously served at a university technology transfer platform, where I incubated and invested in over thirty enterprises commercializing scientific and technological achievements. I have accumulated extensive experience in evaluating technology transfer projects, selecting commercialization pathways, establishing and developing technology transfer enterprises, risk mitigation, and corporate financing.
Cai Yuxuan
Shenzhen Bay Laboratory, Distinguished Researcher
Cai Yuxuan,Shenzhen Overseas High-Level Talent; recipient of the 2021 National Natural Science Foundation of China Excellent Young Scientists Fund (Overseas), British Science Association Media Fellowship (2018), GW4 Crucible (2017), and EMBO Fellowship (2014). He earned his B.S. in Chemistry from National Taiwan University, his M.S. from ETH Zurich, and his Ph.D. from Freie Universität Berlin/Max Planck Institute of Colloids and Interfaces. He completed his postdoctoral training at the MRC Laboratory of Molecular Biology in the UK. In 2015, he established an independent research group at Cardiff University, UK, and joined Shenzhen Bay Laboratory in 2020. To date, he has delivered over 30 invited lectures at academic conferences and research institutions and has published a total of 42 papers. His research group is dedicated to interdisciplinary studies at the intersection of chemistry and biomedicine, aiming to address critical challenges in life sciences by developing novel methods and technologies, thereby providing new tools and insights for disease diagnosis and treatment. The group possesses expertise in chemical biology, chemical synthesis, drug development, gene editing, and genetic code expansion technology, with a focus on regulating protein activity and applying these findings to the diagnosis and treatment of diseases such as cancer.
Chen Zhicheng
Shenzhen Bay Laboratory Center for Translational Medicine
Senior Translational Researcher
Dr. Chen Zhicheng specializes in the development of checkpoint inhibitors and TCR-mimic antibody therapeutics for oncology. With over a decade of experience in the biopharmaceutical industry, he previously engaged in drug R&D at ABM in Canada, where he participated in multiple blockbuster antibody new drug development projects and successfully identified more than ten antibody drug candidates with anti-tumor activity. Dr. Chen founded AbCura Pharmaceuticals in Canada, serving as its Chief Executive Officer and Chief Scientific Officer, leading the development of immuno-oncology antibody drugs and the discovery of novel drug targets. He holds a Master’s degree in Immunology from the Academy of Military Medical Sciences of China and a Ph.D. in Physiology from the University of Saskatchewan, Canada, and completed his postdoctoral research at Harvard Medical School in the United States. His research articles have been published in prestigious journals such as Nature, Nature Communications, Alzheimer's & Dementia, and Journal of Neuroscience. Dr. Chen has received the Young Scientist Award at the International Proteomics Conference and has been recognized under Guangdong Province’s Pearl River Talent Program and Shenzhen’s Overseas High-Caliber Personnel “Peacock Plan.”
Kangxi
Shenzhen Bay Laboratory, Center for Translational Medicine
Gene and Cell Therapy PlatformResearcher
Kang Xi,Earned bachelor’s, master’s, and doctoral degrees from the College of Life Sciences at Wuhan University. During his tenure in the United States, he conducted research on cellular immunotherapies for antiviral applications and oncology at Baylor College of Medicine, the University of Southern California, and Boston University. His work primarily encompassed CAR-T, CAR-NK, oncolytic viruses, TCR cloning, and DC vaccines. He subsequently served as the Head of Upstream Technology Development at Galaxy Marino and Senti Bioscience, where he oversaw preclinical studies for multiple pipelines and facilitated their approval for clinical trials. He has published numerous papers in journals such as Nature Medicine and Nature Communications, and has filed multiple patents in the United States, Europe, Japan, and China.
Wang Wenhao
Director of Biomaterials R&D, Zhongke Ruiji
Wang Wenhao, Director of Biomaterials R&D at Zhongke Ruiji. Associate Professor at Guangzhou Medical University; Ph.D. from the Department of Orthopaedics and Traumatology, Li Ka Shing Faculty of Medicine, The University of Hong Kong. He has long been dedicated to the clinical translational research of bone tissue repair and regenerative medicine, published more than 20 SCI papers with a cumulative impact factor exceeding 100, among which one paper has received over 1,200 citations and was selected as an ESI top 1% highly cited paper in its field. He has filed more than ten patents, and served as principal investigator or co-investigator for six projects, including the National Natural Science Foundation of China (Young Scientists Fund), securing total project funding of over RMB 18 million. He later co-founded Zhongke Ruiji and serves as the Director of the Biomaterials Department.
Read by Director Tong
LaiMang Biotech, R&D Director
Dr. Tong Du obtained his bachelor’s degree from the University of Science and Technology of China and his Ph.D. from Nanyang Technological University in Singapore. He completed multiple postdoctoral fellowships at institutions such as the University of Chicago in the United States. His research focuses on computational chemistry and protein design, with more than 10 research papers published in journals including Biophys. J. Currently, he is working at Lemeng Bio on building an AI-driven drug discovery platform and optimizing the design of metabolic enhancement factors.
Zhou Qihao
Vice President, Yeasen Biotechnology
Zhou Qihao joined Yeasen in 2013, advancing from a frontline sales representative to the company’s Vice President of Marketing. He possesses extensive practical experience in business operations and deep industry insights.
Huang Rui
GeneCopoeia, Executive President
Huang Rui, Executive President of VectorBuilder, holds a Master of Laws from Sun Yat-sen University and is currently pursuing a Master’s degree in Biology at Jinan University. He previously served in the Guangdong Provincial Government and Liandong Group. With over ten years of experience in business management and project investment, he is currently responsible for strategic affairs, external relations, brand marketing, and comprehensive administrative operations at VectorBuilder.
Liu Bin
Shenyan Biotech, Chief Marketing Officer
Liu Bin, a graduate of the Hong Kong University of Science and Technology, has dedicated over 16 years to the life sciences sector. He has played a key role in supporting the research and development (R&D) and Investigational New Drug (IND) applications for cell and gene therapy (CGT) products. Mr. Liu possesses extensive experience in business development, project management, product R&D, current Good Manufacturing Practice (cGMP) compliance, and IND submissions. Currently, he is responsible for formulating R&D and market strategies for CGT technologies and products at Shenyen Biologics, as well as driving global business collaboration initiatives.
Li Yuanyuan
CEO of Sanqi Biotech
Li Yuanyuan,Graduated from Sun Yat-sen University in 1998, he worked in the financial industry for 14 years before venturing into the real economy in 2013. He co-founded Sanqi Biologics with a team of scientists returning from overseas, focusing on the development of somatic cell reprogramming and gene editing technology platforms as well as product translation. Currently, the company is strategically prioritizing the development of universal immune cell novel drugs based on human induced pluripotent stem cells (iPSCs).
Zhou Yuan
Aipu Regenerative Medicine
Senior Vice President
Zhou Yuan,Co-founder of Nanjing Alpu Regenerative Medicine Technology Co., Ltd.; Ph.D. in Biomedicine from the University of Macau. Possesses extensive practical experience and expertise in industrial translation within the fields of stem cells and regenerative medicine, with particular strengths and unique insights in understanding and planning industrial policies, large-scale production technologies, and promoting clinical applications.
Li Fusheng
Chairman of Navie Vaccine
Li Fusheng, Ph.D. from the Chinese Academy of Preventive Medicine, Postdoctoral Fellow at the University of Washington, Researcher at the Fred Hutchinson Cancer Research Center in the United States, and Chairman of Shenzhen Navai Vaccine Technology Co., Ltd. He has long been engaged in basic and applied research on vaccines both domestically and internationally, leading the laboratory development and clinical trials of multiple infectious disease and tumor vaccines. He has received support from the Bill & Melinda Gates Foundation, China’s National Special Project for Infectious Diseases, and the U.S. National Institutes of Health (NIH) on multiple occasions. He pioneered the Virus-Like Nanoparticle (VLNP) vaccine technology platform, focusing on the development of therapeutic cancer vaccines, with several investigational therapeutic cancer vaccines progressively entering clinical studies and applications.
Yang Zhenhuang
iDBIOFounder & CEO
Yang Zhenhuang graduated with a degree in Molecular Medicine from the University of Lübeck, Germany, in 2016. He completed his postdoctoral training at the Immunotherapy Platform of the MD Anderson Cancer Center in the United States, under James Allison, the 2018 Nobel Laureate in Physiology or Medicine. In 2020, he returned to China and joined Nanjing Drum Tower Hospital as a specially appointed Associate Researcher. In 2022, he founded Aidibeike, focusing on the development and application of CRISPR-based gene and cell therapies. With over ten years of research experience in the biomedical field, particularly in cell therapy and gene editing, he possesses comprehensive expertise spanning from mechanistic studies to clinical applications.
Wang Mingjun
InnoImmune, Executive Vice President & CEO
Wang Mingjun, Executive Dean of the Shenzhen InnoTranslational Medicine Research Institute, and Executive Deputy General Manager and CEO of Shenzhen InnoImmune Co., Ltd. He holds a Ph.D. in Immunology from the University of Copenhagen, Denmark, and completed his postdoctoral training at Baylor College of Medicine in Houston, USA. His primary focus is on the research, development, translational medicine, and industrialization of tumor cell immunotherapy products. He has published more than 30 SCI-indexed academic papers and authored three book chapters. He has been honored with the Chinese Medical Association Young Scientist Award, the First Prize of the Guangdong Medical Science and Technology Award, the title of “Annual Emerging Entrepreneur” in the Individual Category of the “2018 Shenzhen Innovation List,” the National Outstanding Self-Funded Overseas Student Scholarship, recognition as an Overseas High-Level Talent under Shenzhen’s “Peacock Plan,” designation as an Outstanding Expert under Shenzhen Dapeng New Area’s “Pengcheng Plan,” and the title of Outstanding Communist Party Member of Shenzhen. He is a member of the Society for Immunotherapy of Cancer (SITC), a deputy to the 7th Shenzhen Municipal People’s Congress, Vice President of the Shenzhen Western Returned Scholars Association, President of the Shenzhen Dapeng New Area Association of Overseas Returnees, Council Member of the Shenzhen Overseas Exchange Association, Council Member of the Shenzhen Biopharmaceutical Promotion Association, and Vice President of the Shenzhen Life Sciences and Biotechnology Association.
Chen Yi
Regen Biotech, CFO
Chen Yi, Chief Financial Officer of Ruiji Biologics, holds a Bachelor’s degree in Economics and Finance from the University of Hong Kong and an MBA in Finance from CEIBS (China Europe International Business School). He is a Certified Public Accountant with the Hong Kong Institute of Certified Public Accountants. With over 16 years of experience in finance, audit, and financial services, Mr. Chen previously served as an auditor and M&A due diligence consultant at PwC. He also held roles in corporate strategy and investment planning at a foreign bank and a Chinese investment group. Prior to joining Ruiji Biologics, he served as CFO at two startup companies. Mr. Chen joined Ruiji Biologics in 2021, overseeing financial management and investor relations.
Ji Qianqian
Shenzhen High-Tech Innovation Venture Capital – Senior Investment Manager
Ji Qianqian, Ph.D. in Biology from Sun Yat-sen University, Senior Engineer in Biotechnology, has nearly ten years of experience in research and development of biopharmaceutical technologies as well as equity investment.
*The above guests are listed in agenda order, not in any particular order.
Company Profile
Xingcheng Bio
Yeasen Biotechnology
LePure Biotech
Shanghai Lepu Biotechnology Co., Ltd., established in 2011, has integrated outstanding brands such as Geshi Fluid, Kangsheng Biology, and Stanley’s through an external growth strategy. Its business scope now covers multiple application scenarios, including cell culture, filtration and purification, single-use systems, and industrial-grade contamination-free clean solutions. The company has become a widely recognized leading supplier providing end-to-end upstream biopharmaceutical processing solutions.
Mission & Vision: Driven by technological innovation, we provide high-quality bioprocessing solutions and are committed to becoming the most trusted partner for global biopharmaceutical companies.
Yunzhou Biotech
VectorBuilder (Guangzhou) Biotechnology Co., Ltd. was founded in 2014 by Dr. Lan Tian, a world-renowned molecular biologist, and has emerged as a leading enterprise in gene delivery. The company provides comprehensive services across the entire gene delivery industry chain, including research vector construction, gene delivery CRO, and gene vector CDMO. With more than 10 subsidiaries and offices worldwide, VectorBuilder was recognized as a global unicorn in 2023. Its proprietary "VectorBuilder" platform pioneered the era of commercialized custom gene vectors, serving over 4,000 research institutions and pharmaceutical companies in more than 90 countries and regions. Its contributions have been widely cited in thousands of articles published in top-tier scientific journals such as Science, Nature, and Cell. Since entering the clinical market, its gene therapy CRO and CDMO projects have expanded to cover multiple countries and regions, including North America, Europe, and Japan.
Yunzhou Biotech provides end-to-end services from research to clinical applications:
(1) Research Vectors and Viral Services: vector construction, viral packaging, etc.
(2) CRO Services: AAV capsid directed evolution, library construction, mRNA gene delivery solutions, stable cell line generation, etc.
(3) CDMO Services: Process development, analytical method development, plasmid preparation, virus preparation, IVT mRNA and LNP preparation, cell bank establishment, etc.
Yunzhou Biotech is committed to systematically overcoming key technical bottlenecks in the gene delivery industry, empowering basic scientific research, accelerating the clinical application of gene therapies, improving human health, and creating irreplaceable value for the world.
Danaher Life Sciences
At Danaher, we converge science, technology, and operational expertise to accelerate the impact of future technologies on today’s lives. Partnering with customers worldwide, we build solutions that address their most complex challenges, turning the power of science into reality. Our global team is shaping the future of life sciences, medical diagnostics, biotechnology, and more. The Danaher Life Sciences platform serves leading life sciences companies globally, accelerating breakthrough innovations to enable healthier lives for humanity. We maintain long-term collaborations with scientists in research, clinical, and government institutions, leveraging our strengths in science and operations to help them deepen their understanding of disease principles and mechanisms, develop more effective therapies, and create more efficient workflows. Together, we are accelerating the positive impact of life sciences on human life.
Danaher China Life Sciences Platform was established on June 1, 2019, with the aim of rooting itself in the Chinese market to provide better products and services to users in China, focusing on creating comprehensive integrated solutions for precision medicine and biopharmaceuticals. The platform currently boasts many well-known brands, including IDT, Beckman Coulter Life Sciences, Molecular Devices, SCIEX, Agela-Phenomenex, Leica Microsystems, Aldevron, and Pall. In the fields of precision medicine and biologics, Danaher Life Sciences continuously develops and refines relevant analytical solutions and workflows based on the actual application scenarios of Chinese customers. It currently offers rich, multi-dimensional solutions in areas such as synthetic biology, multi-omics research, organoid research, precise tumor diagnosis and treatment, infectious disease testing, and maternal and child health testing. Furthermore, it provides comprehensive, mature, and highly competitive integrated solutions covering everything from R&D to quality control analysis for a wide range of biologics, including antibody drugs, gene therapies, cell therapies, nucleic acid drugs, and novel vaccines.
Shenyan Biotech
Founded in 2014, Deep Research Biotech is a core upstream supplier in the field of cell and gene therapy (CGT), providing leading technical services and production tools to CGT enterprises, including viral vector production solutions and comprehensive solutions for cell-based drug manufacturing.
In the viral vector production solutions segment, Deep Bioscience has designed and implemented its proprietary EuBioX automated laboratory system. By integrating advanced technologies such as big data analytics, bioinformatics, and automation, the company has innovatively developed the EuLV® system for large-scale lentiviral vector production using stable producer cell lines. This breakthrough addresses the technical bottlenecks associated with scaling up lentiviral vector manufacturing, leveraging globally leading technology to significantly enhance production efficiency and product consistency while substantially reducing production costs.
Meanwhile, as a leading domestic enterprise in automated cell preparation equipment, Deep Biotech has independently developed the CellSep® series of cell processing systems, which are suitable for the standardized production of various cell-based therapies. The company has also launched equipment such as sterile tube welders, heat sealers, and wave bioreactors, providing comprehensive automated solutions for cell therapy manufacturing and significantly enhancing production efficiency.
Shenyan Bio possesses unique interdisciplinary advantages and has accumulated profound technical expertise in the field of cell and gene therapy (CGT). Upholding its mission to “empower CGT and solve the industry’s most challenging problems,” the company will continue to expand the frontiers of therapeutic innovation.
Lingfu TopBio
Shenzhen Lingfu Top Biotechnology Co., Ltd. (hereinafter referred to as “Lingfu Top”), established in 2015, is an innovative contract research organization (CRO) specializing in animal-based scientific research and serving preclinical studies and evaluations. Centered on animal models, the company provides one-stop services encompassing cell biology, pathology, proteomics, molecular biology, biochemistry, and behavioral studies, thereby empowering life science and biopharmaceutical research. Lingfu Top operates R&D bases and laboratory animal centers in Nanshan, Guangming, and Pingshan Districts of Shenzhen, as well as in Guangzhou, offering preclinical CRO services including medical device evaluation, development of small and large animal models, drug screening and evaluation, and animal husbandry. The company has successively obtained certifications and honors such as National High-Tech Enterprise, Specialized and Sophisticated SME, and Quality Management System certification. With a core R&D and professional technical team, Lingfu Top is committed to becoming a leading brand in animal research services across China, realizing its vision of “a world where no disease is difficult to treat.”
Hanhuang Technology
Jiangsu Hanhuang Technology Co., Ltd. is a wholly-owned subsidiary of Hanbang Technology, specializing in the research and development, production, and sales of laboratory chromatography instruments. The company focuses on chromatographic analysis, separation instruments, and technologies in the fields of chemistry, biology, pharmaceuticals, and food. It offers its own branded product lines, including laboratory- and pilot-scale small- and medium-to-high-pressure preparative chromatography systems, low-pressure purification systems for biological macromolecules, ultrafiltration systems, as well as supercritical fluid chromatography and continuous chromatography solutions ranging from laboratory to production scale.
Tongli Haiyuan Biology
Beijing Tongli Haiyuan Biotechnology Co., Ltd. specializes in the research, development, and manufacturing of GMP-grade raw materials and reagents for cell and gene therapy (CGT), providing comprehensive product and service solutions for CGT users. Its product portfolio includes magnetic beads for cell sorting, eukaryotic/prokaryotic recombinant proteins, serum-free culture media, and cell culture kits.
The Company has been honored with titles such as “National High-Tech Enterprise” and “Beijing Specialized, Refined, Differential, and Innovative (SRDI) Small and Medium-sized Enterprise.” It operates a 3,200 m² R&D laboratory and GMP-grade cleanroom facilities, encompassing platforms for cell separation magnetic bead development, eukaryotic and prokaryotic protein expression engineering, and serum-free culture medium development. The Company is certified under both ISO 13485 and ISO 9001 quality management systems, and certain products have obtained U.S. FDA Drug Master File (DMF) filings.
Legend Capital
Legend Capital was established in April 2001 and is a leading fund management firm in China specializing in early-stage venture capital and growth-stage private equity investment. Over the past two decades, Legend Capital has adhered to international standards, establishing best practices in fund operations and management. Through its proactive value-added service system, Legend Capital fosters innovative corporate growth, delivering consistent strong investment returns across multiple sectors while driving industrial advancement and social development in China. With the vision of becoming an internationally influential investment firm, Legend Capital upholds the core value of “Prosperity with Integrity” and actively fulfills its social responsibilities.
Legend Capital maintains a deep focus on investments in the healthcare and medical sector, systematically deploying capital across the broader health industry. In this field, it has backed several leading companies in niche segments that are listed on both the A-share and Hong Kong stock markets, including Pharmaron (300759.SZ) (03759.HK), WuXi AppTec (603259.SH) (02359.HK), WuXi Biologics (02269.HK), Innovent Biologics (01801.HK), New Horizon Health (06606.HK), and Mingde Biology (002932.SZ).
Weiguang Life Science Park
Weiguang Life Science Park, invested and constructed by the listed company Weiguang Biology and operated by Times High-Tech for project commercialization, is China’s first specialized biomedical industrial park distinguished by the translation of synthetic biology achievements. The park focuses on the commercialization of scientific and technological achievements, primarily hosting projects and enterprises engaged in the R&D and production of antibody macromolecules, novel vaccines, gene therapy, cell therapy, new bio-regenerative materials, medical devices, and in vitro diagnostic reagents. It aims to build a modern, intelligent, and standardized industrial cluster with a professional focus on the commercialization of synthetic biology outcomes, providing an innovative development and translation platform that aggregates industry-specific advantages. Highlighted by “the highest level of specialization, the most comprehensive public supporting facilities, and the best regional advantages,” the park integrates production, living, and ecological environments.
Bay Gravity
Bay Gravity (Guangming Biomedical Innovation Center) is a biomedical industry incubation platform jointly established by the Guangming District Government and Shenzhen Bay Laboratory. It aims to create a showcase for Shenzhen’s source innovation benchmark projects and a hub for biomedical resource aggregation. Guided by the goal of fully supporting scientists and physicians in their entrepreneurial and innovative endeavors, and characterized by providing a one-stop acceleration experience, it focuses on identifying source-innovation projects represented by cell and gene therapy, AI-driven drug discovery, and high-end medical imaging. Bay Gravity is committed to providing deep entrepreneurial empowerment services to biomedical startups, including high-specification incubation spaces, shared instruments and equipment, fund and capital matchmaking, clinical resource linkage, scientific and technical support, and industrial resource connectivity, thereby truly achieving comprehensive “from 0 to 1” incubation and empowerment.
VBHealth
VB Pharma, a media and research platform under VCBeat focused on biopharmaceuticals, delivers “in-depth” and “incremental” communication value to innovators and entrepreneurs through both content and operations. In terms of content, it features exclusive financing announcements, corporate interviews, the “Drug Developers” column, in-depth industry analyses, and sector reports. On the operational front, its flagship brand program, “VB Think Tank,” focuses on practical challenges, discusses industrial trends, and fosters tangible collaborations through intellectual exchange.
*The above institutions are listed in agenda order, not in any particular order.
Event Scale: 50 people/session
Event Collaboration:
Ms. Fu 17851017836 (WeChat ID same)
Event Registration:
Capillaries 17782369627 (WeChat ID same)
Previous Reviews